Study identifier:D7811C00001
ClinicalTrials.gov identifier:NCT05246514
EudraCT identifier:N/A
CTIS identifier:N/A
An Open-label, Single-arm, Phase 2 Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd) for Patients with HER2-mutant Metastatic NSCLC who have Disease Progression on or after at Least One-line of Treatment (DESTINY-Lung05)
HER2-mutant Non-Small Cell Lung Cancer
Phase 2
No
Trastuzumab deruxtecan
All
72
Interventional
18 Years - n/a
Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Nov 2024 by AstraZeneca
AstraZeneca
Daiichi Sankyo
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: T-DXd arm Participants will receive T-DXd as an IV infusion Q3W, on Day 1 of each 3-week cycle. | - |